| Item No. | API name | DMF | Tech Pack |
| USDMF | EU-DMF (ASMF) | JP-MF | CHN |
| 001 | Ambroxol Hydrochloride | * |
|
| √ | √ |
| 002 | Brivaracetam | * |
|
| √ | √ |
| 003 | Bromhexine Hydrochloride | * |
|
| √ | √ |
| 004 | Buthiazide |
| * |
| √ | √ |
| 005 | Cabazitaxel | * |
|
| √ | √ |
| 006 | Carbimazole | √ |
|
| √ | √ |
| 007 | Caroverine | * |
|
| √ | √ |
| 008 | Caroverine Hydrochloride | * |
|
| √ | √ |
| 009 | Ceftaroline Fosamil | √ |
|
| √ | √ |
| 010 | Clomethiazole | * | √ |
| √ | √ |
| 011 | Clomethiazole Edisilate | * |
|
| √ | √ |
| 012 | Dectaflur |
|
|
| √ | √ |
| 013 | Desvenlafaxine | * |
|
| √ | √ |
| 014 | Distigmine Bromide | √ |
|
| √ | √ |
| 015 | Ethacridine Lactate Monohydrate | √ |
|
| √ | √ |
| 016 | Etofenamate | * |
|
| √ | √ |
| 017 | Flufenamic acid |
| * |
| √ | √ |
| 018 | Flurbiprofen | √ |
|
| √ | √ |
| 019 | Ipratropium Bromid | * |
| △ | √ | √ |
| 020 | Isradipine | * |
|
| √ | √ |
| 021 | Labetalol hydrochloride | * |
|
| √ | √ |
| 022 | Macitentan | * |
|
| √ | √ |
| 023 | Metaraminol Bitartrate | √ |
|
| √ | √ |
| 024 | Methimazole | √ |
|
| √ | √ |
| 025 | Metoclopramide Hydrochloride | * |
|
| √ | √ |
| 026 | Naftazone | * |
|
| √ | √ |
| 027 | Olaflur |
|
|
| √ | √ |
| 028 | Phenazopyridine Hydrochloride | * |
|
| √ | √ |
| 029 | Polaprezinc | √ |
|
| √ | √ |
| 030 | Propylthiouracil | √ |
|
| √ | √ |
| 031 | Semaglutide | √ |
|
| √ | √ |
| 032 | Sugammadex Sodium | √ |
|
| √ | √ |
| 033 | Teneligliptin Hydrobromide | * |
|
| √ | √ |
| 034 | Thymalfasin | √ |
|
| √ | √ |
| 035 | Tiopronin | √ |
|
| √ | √ |
| 036 | Tretinoin | * |
|
| √ | √ |
| 037 | Tripeptide | √ |
|
| √ | √ |
| 038 | Ufenamate | * |
|
| √ | √ |
| 039 | Vortioxetine | * |
|
| √ | √ |
|
|
|
|
|
|
|
Note: Above products will NOT be supplied to countries in which these could be in conflict with existing patents.
The final responsibility lies exclusively with the buyer. |
|
|
|
|
|
|
|
| Mark | Meaning |
|
|
|
|
|
| √ | Ready |
|
|
|
|
|
| * | Preparing |
|
|
|
|
|
| △ | Planning |
|
|
|
|
|
|
|
|
|
|
|
|
